Insider Selling: Abbott Laboratories (NYSE:ABT) EVP Sells $30,397.54 in Stock

Abbott Laboratories (NYSE:ABT) EVP Elizabeth Cushman sold 263 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $30,397.54. Following the sale, the executive vice president directly owned 38,573 shares of the company’s stock, valued at approximately $4,458,267.34. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Abbott Laboratories Price Performance

NYSE ABT opened at $110.97 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The business’s fifty day moving average is $116.39 and its 200 day moving average is $124.82. The company has a market capitalization of $192.83 billion, a PE ratio of 29.83, a price-to-earnings-growth ratio of 1.80 and a beta of 0.74. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $139.15.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $25,000. Cornerstone Financial Management LLC purchased a new position in Abbott Laboratories during the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at $26,000. Abound Financial LLC bought a new stake in shares of Abbott Laboratories in the 4th quarter worth about $26,000. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter worth about $27,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ABT. Sanford C. Bernstein dropped their price objective on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Royal Bank Of Canada dropped their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Evercore reduced their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Finally, Barclays cut their target price on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.